Oncology and Immunotherapy Pipeline

At Protheragen, we are actively seeking collaboration opportunities to license our ImmuBridge™ multispecific antibody platform or co-develop multispecific antibody drug candidates. Leveraging the potential of next-generation TCEs, our goal is to revolutionize the fight against cancer by precisely targeting malignant cells with unparalleled precision and efficacy. By reshaping the landscape of oncology and immunotherapy, we aim to set new standards in cancer therapeutics, advancing the boundaries of medical science.

If you are interested in any of the projects, please contact us for further discussion. We look forward to our collaboration.